Podcasts about low dose

Cada vez mais pessoas têm contato com o uso de Ayahuasca e dos famosos "cogumelos mágicos". Mas pouco se sabe sobre os impactos que essas substâncias têm na nossa saúde. O que a ciência sabe, hoje, sobre isso? Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza. >> OUÇA (57min 07s) * SOBRE O NARUHODO Naruhodo! (@naruhodopodcast) é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka (@kenfujioka), e o cientista PhD, Altay de Souza (@altayals). Edição: Reginaldo Cursino (@reginaldocursino) Ilustração e Capa: Felipe Cruz (@felipecruzart) http://naruhodo.b9.com.br * REFERÊNCIAS Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca https://www.ingentaconnect.com/content/ben/cdar/2014/00000007/00000002/art00005 A Systematic Review on the Therapeutic Effects of Ayahuasca https://www.mdpi.com/2223-7747/12/13/2573 Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science https://www.jsad.com/doi/abs/10.15288/jsad.23-00005 Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1484736/full The Future of the Biopsychosocial Model: Toward a Transdisciplinary Systems Science of Mental Health  https://media.eiko-fried.com/publications/2026-robinaugh-clinical-psychological-science-the-future-of-the-biopsychosocial-model.pdf Lopes, Inês Magalhães (2017). Do Kamo, Ser-no-mundo e a Universalização da Concepção Individualista de Pessoa (PDF). Lisboa: Instituto Universitário de Lisboa, Escola de Ciências Sociais e Humanas The Legacy of Maurice Leenhardt https://journals.sagepub.com/doi/10.1177/239693938901300408 Ayahuasca and the traveller: A scoping review of risks and possible benefits https://www.sciencedirect.com/science/article/abs/pii/S1477893921002477 Mental Disorders as Homeostatic Property Clusters A Narrative Review  https://media.eiko-fried.com/publications/2026-fried-jama-psychiatry-mental-disorders-as-homeostatic-property-clusters-a-narrative-review.pdf Revisiting the theoretical and methodological foundations of depression measurement  https://media.eiko-fried.com/publications/2022-fried-nature-reviews-psychology-revisiting-the-theoretical-and-methodological-foundations-of-depression-mea.pdf Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela https://pubmed.ncbi.nlm.nih.gov/19004422/ Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial https://pmc.ncbi.nlm.nih.gov/articles/PMC6378413/ The Psychedelic Future of Post-Traumatic Stress Disorder Treatment https://www.benthamdirect.com/content/journals/cn/10.2174/1570159X22666231027111147 Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review https://journals.sagepub.com/doi/full/10.1177/02698811231180276 How to set up a psychedelic study: Unique considerations for research involving human participants https://www.sciencedirect.com/science/article/pii/S0149763426001144 Psycholytic Therapy Using LSD: a Realist Review https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.71187 Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2831639 Preliminary Findings on Low-Dose 1cp-LSD for Canine Anxiety: Exploring the Role of Owner Neuroticism and Psychopathology https://www.mdpi.com/2306-7381/12/9/872 Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials https://www.sciencedirect.com/science/article/abs/pii/S0165178125002707 Evaluating the Impact of a Low Dose of LSD on EEG Spectral Signature in Participants with Depressed Mood (Abstract ID: 163720) https://jpet.aspetjournals.org/article/S0022-3565(24)42708-0/fulltext Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial https://www.cell.com/med/fulltext/S2666-6340(25)00152-7 Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial  https://repositorio.ufrn.br/server/api/core/bitstreams/79cb4dd8-9bca-4b4a-832b-b6940029b65b/content Naruhodo #266 - Por que vemos luzes quando fechamos os olhos?  https://www.youtube.com/watch?v=3_4r_ZGb4wA Naruhodo #220 - Existe causa para a depressão? - Parte 1 de 2  https://www.youtube.com/watch?v=cFo8GFwyuR0 Naruhodo #221 - Existe causa para a depressão? - Parte 2 de 2  https://www.youtube.com/watch?v=5peXBmG43lU Naruhodo #419 - Maconha faz mal? - Parte 1 de 2  https://www.youtube.com/watch?v=cvLTh2bKPiQ Naruhodo #420 - Maconha faz mal? - Parte 2 de 2  https://www.youtube.com/watch?v=F7wVcGvpoGA Naruhodo #106 - Hipnose funciona? - Parte 1 de 2  https://www.youtube.com/watch?v=XIHUilfmAzQ Naruhodo #107 - Hipnose funciona? - Parte 2 de 2  https://www.youtube.com/watch?v=O42Yo2zt5vs Naruhodo #461 - O que é a teoria da Incompletude de Godel?  https://www.youtube.com/watch?v=XQRu2ogFvMQ * APOIE O NARUHODO! O Altay e eu temos duas mensagens pra você. A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos. A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano. Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar. A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar. A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser.  O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON. É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder. bit.ly/naruhodo-no-orelo

Ketamine clinics have exploded worldwide, offering low-dose intravenous infusions for chronic pain patients who've run out of options. But is this practice actually backed by evidence, or has off-label use outpaced the science? In this episode, Dr. David Rosenblum reviews the current literature on subanaesthetic-dose ketamine infusions (SDKIs) for chronic pain, drawing on the 2023 British Journal of Pain review by Harry M. Griffiths, "Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?" Topics covered: Why conventional analgesics (opioids, anticonvulsants, antidepressants) fail in 60-70% of chronic pain patients - How ketamine works as an NMDA receptor antagonist, and why that mechanism is likely an oversimplification - Typical SDKI dosing (~0.35-0.5 mg/kg) versus anesthetic dosing, and why the IV route dominates the evidence base - What the meta-analyses actually show: modest, time-limited pain reduction with higher efficacy but more side effects at higher doses - Key trials, including Corriger et al.'s 1-year follow-up (256 patients) and Orhurhu et al.'s systematic review and meta-analysis - Common side effects (nausea, psychomimetic symptoms) versus rare but serious adverse events, and how premedication with clonidine/midazolam affects risk - Why blinding failure may be inflating reported effect sizes - The absence of standardized protocols, guidelines, or a clear "exit strategy" for long-term SDKI therapy Bottom line: SDKIs offer a promising but still under-evidenced option for refractory chronic pain, reserved for the right patient with modest expectations and careful monitoring.   Reference: Griffiths HM. Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice? Br J Pain. 2023;17(5). https://journals.sagepub.com/doi/full/10.1177/20494637231182804   This episode is brought to you by NRAP Academy and PainExam - visit www.NRAPpain.org for CME in neuromodulation, regional anesthesia, and pain medicine.    

Ketamine clinics have exploded worldwide, offering low-dose intravenous infusions for chronic pain patients who've run out of options. But is this practice actually backed by evidence, or has off-label use outpaced the science? In this episode of the PainExam Podcast, Dr. David Rosenblum reviews the current literature on subanaesthetic-dose ketamine infusions (SDKIs) for chronic pain, drawing on the 2023 British Journal of Pain review by Harry M. Griffiths, "Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?" Topics covered: Why conventional analgesics (opioids, anticonvulsants, antidepressants) fail in 60–70% of chronic pain patients How ketamine works as an NMDA receptor antagonist, and why that mechanism is likely an oversimplification Typical SDKI dosing (~0.35–0.5 mg/kg) versus anesthetic dosing, and why the IV route dominates the evidence base What the meta-analyses actually show: modest, time-limited pain reduction (mean difference around -1.83 on a 0–10 scale) with higher efficacy but more side effects at higher doses Key trials — Corriger et al.'s 1-year follow-up (256 patients), Orhurhu et al.'s systematic review and meta-analysis, and smaller RCTs in CRPS, fibromyalgia, and ischemic limb pain Common side effects (nausea, psychomimetic symptoms) versus rare but serious adverse events (hepatic, cardiac, urogenital) — and how dose and premedication with clonidine/midazolam affect risk Why blinding failure (up to 93% of patients correctly guessing their treatment in one trial) may be inflating reported effect sizes The absence of standardized protocols, guidelines, or a clear "exit strategy" for patients on long-term SDKI therapy What needs to happen next: larger multicenter RCTs, ketamine clinic registries, and better outcome measures beyond simple pain scores Bottom line: SDKIs offer a promising but still under-evidenced option for refractory chronic pain — reserved for the right patient, with modest expectations and careful monitoring. Reference: Griffiths HM. Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice? Br J Pain. 2023;17(5). https://journals.sagepub.com/doi/full/10.1177/20494637231182804 Show Image About the Host David Rosenblum, MD is Director of Pain Management at Maimonides Medical Center and Co-Owner/Clinic Director of AABP Integrative Pain Care and Wellness in Brooklyn, NY. Dual board-certified in Anesthesiology and Pain Medicine, he is a co-author of the ASIPP Peripheral Nerve Stimulation (PNS) guidelines and a widely recognized educator in regenerative pain medicine (PRP, BMAC, amniotic therapies). As founder of NRAP Academy, he has trained 3,500+ physicians for pain board certification since 2008, and hosts the PainExam, AnesthesiaExam, and PMRExam podcasts. He has been named a New York Magazine "Top Doctor" from 2016–2026. Living with chronic pain? Dr. Rosenblum sees patients for interventional and regenerative pain treatment — including epidurals, nerve blocks, spinal cord & peripheral nerve stimulation, and PRP/BMAC — at his Brooklyn, NY office. Visit RosenblumPain.com for more information. For Physicians & APPs — Continue Your Education: CME Course Calendar: https://www.nrappain.org/pages/upcoming-pain-management-conferences Virtual Pain Fellowship: https://www.nrappain.org/bundles/Virtual-Pain-Fellowship PainExam Board Prep: https://www.nrappain.org/pages/pain-management-cme-couåçrses This episode is brought to you by NRAP Academy and PainExam — visit www.NRAPpain.org for CME in neuromodulation, regional anesthesia, and pain medicine.

Ketamine clinics have exploded worldwide, offering low-dose intravenous infusions for chronic pain patients who've run out of options. But is this practice actually backed by evidence, or has off-label use outpaced the science? In this episode of the PainExam Podcast, Dr. David Rosenblum reviews the current literature on subanaesthetic-dose ketamine infusions (SDKIs) for chronic pain, drawing on the 2023 British Journal of Pain review by Harry M. Griffiths, "Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?" Topics covered: Why conventional analgesics (opioids, anticonvulsants, antidepressants) fail in 60–70% of chronic pain patients How ketamine works as an NMDA receptor antagonist, and why that mechanism is likely an oversimplification Typical SDKI dosing (~0.35–0.5 mg/kg) versus anesthetic dosing, and why the IV route dominates the evidence base What the meta-analyses actually show: modest, time-limited pain reduction (mean difference around -1.83 on a 0–10 scale) with higher efficacy but more side effects at higher doses Key trials — Corriger et al.'s 1-year follow-up (256 patients), Orhurhu et al.'s systematic review and meta-analysis, and smaller RCTs in CRPS, fibromyalgia, and ischemic limb pain Common side effects (nausea, psychomimetic symptoms) versus rare but serious adverse events (hepatic, cardiac, urogenital) — and how dose and premedication with clonidine/midazolam affect risk Why blinding failure (up to 93% of patients correctly guessing their treatment in one trial) may be inflating reported effect sizes The absence of standardized protocols, guidelines, or a clear "exit strategy" for patients on long-term SDKI therapy What needs to happen next: larger multicenter RCTs, ketamine clinic registries, and better outcome measures beyond simple pain scores Bottom line: SDKIs offer a promising but still under-evidenced option for refractory chronic pain — reserved for the right patient, with modest expectations and careful monitoring. Reference: Griffiths HM. Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice? Br J Pain. 2023;17(5). https://journals.sagepub.com/doi/full/10.1177/20494637231182804 Show Image About the Host David Rosenblum, MD is Director of Pain Management at Maimonides Medical Center and Co-Owner/Clinic Director of AABP Integrative Pain Care and Wellness in Brooklyn, NY. Dual board-certified in Anesthesiology and Pain Medicine, he is a co-author of the ASIPP Peripheral Nerve Stimulation (PNS) guidelines and a widely recognized educator in regenerative pain medicine (PRP, BMAC, amniotic therapies). As founder of NRAP Academy, he has trained 3,500+ physicians for pain board certification since 2008, and hosts the PainExam, AnesthesiaExam, and PMRExam podcasts. He has been named a New York Magazine "Top Doctor" from 2016–2026. Living with chronic pain? Dr. Rosenblum sees patients for interventional and regenerative pain treatment — including epidurals, nerve blocks, spinal cord & peripheral nerve stimulation, and PRP/BMAC — at his Brooklyn, NY office. Visit RosenblumPain.com for more information. For Physicians & APPs — Continue Your Education: CME Course Calendar: https://www.nrappain.org/pages/upcoming-pain-management-conferences Virtual Pain Fellowship: https://www.nrappain.org/bundles/Virtual-Pain-Fellowship PainExam Board Prep: https://www.nrappain.org/pages/pain-management-cme-couåçrses This episode is brought to you by NRAP Academy and PainExam — visit www.NRAPpain.org for CME in neuromodulation, regional anesthesia, and pain medicine.

Send us Fan MailLithium is one of those molecules most people think they understand, until you zoom out. Yes, it's a time-tested medication for bipolar disorder. But at tiny, trace doses, lithium starts to look like something else entirely: a potential micronutrient with outsized influence on mood stability, inflammation, and brain ageing.We walk through why interest in low-dose lithium is rising in the brain health and longevity world, even as human clinical trials are still early. John and I talk about what lithium is chemically, why it's so bioavailable, how it crosses the blood-brain barrier, and why the kidneys matter more at prescription doses than at supplement-scale milligrams. Then we connect the dots on mechanisms people care about most for neuroprotection: GSK-3 inhibition, support for BDNF, a tilt toward calming inhibitory signalling (GABA), better balance in serotonin pathways, and less glutamate-driven mitochondrial stress.We also wrestle with the bigger public health angle: what happens when we treat chronic disease as “too much of everything” and ignore deficiency and nourishment. Soil mineral depletion, variable food mineral content, and strong population associations with lithium in drinking water (including mental health measures and Alzheimer's mortality) make this a conversation worth having, carefully and objectively.For slides and open-source references: www.thehealthedgepodcast.comIf this sparks questions for you, subscribe, share it with a friend, and leave a review so more people can find the show.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood. Dr. Zoller discusses "Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.  Dr. Ribeiro discusses "A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial" and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.

What if the key to better sleep, faster recovery, and long-term brain health is a trace mineral that was once in your drinking water — and quietly removed? In this episode, I sit down with Sudhir, a board-certified psychiatrist, Navy veteran, and co-founder of Third Element, to explore the surprising science behind lithium microdosing — and why it's nothing like the high-dose psychiatric treatment you may have heard of.Sudhir breaks down how low-dose lithium works at the cellular level — from calming the GSK3 enzyme and protecting mitochondria, to extending telomere length and reducing chronic inflammation. He shares why everyone from autistic children to elite NBA and NFL athletes are now evaluating the supplement for athlete recovery, what epidemiological data from blue zones and ancient springs reveals about this overlooked mineral, and how his work with homeless patients, veterans, and addiction populations first proved its safety and efficacy.Whether you're an executive managing stress and sleep, an athlete chasing faster recovery, or simply someone who wants to age better — this conversation will change the way you think about what your brain needs to thrive. Third Element isn't just a supplement; it's the missing piece in a polluted and diluted modern diet.www.imperfectleaders.com

In this episode of Beyond The Abstract, Dr. Kathleen Adams stops by to talk about her new article Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review featured in the May/June issue of the Journal of Addiction Medicine.   Article Link: Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review

Dr. John Plastaras offers the insight of a clinician researcher to an engaging discussion of the emergence and application of low-dose radiation therapy as a non-invasive, non-pharmacologic alternative for chronic and refractory osteoarthritis in individuals seeking relief from chronic joint pain when other treatments fail.  Learn more about Logan Barnes, PA-C  Learn more about John Plastaras, MD, PhD

In this episode of Drugs N Stuff, we answer your steroid and PED questions covering TRT, Tren, Deca, NPP, gyno prevention, contest prep cycles, growth hormone, and more. We also discuss cycle design, nandrolone, androgen receptor sensitivity, and the practical decisions lifters face when planning their next phase. Plus, Dave shares another chapter of Dave the Fugitive and we answer a wide range of audience questions. 0:00 Support Our Sponsors 1:35 Growth Hormone Banned in China? What It Means 8:30 Are Steroids in Ampules Harder to Counterfeit? 19:30 How to Minimize Gynecomastia Risk 22:00 TRT vs Coming Off Cycle | Androgen Receptor Sensitivity 31:00 When to Add a Second Compound to Testosterone 34:20 Injectable YK-11 Feedback & Experiences 35:15 Low Dose Tren for a Summer Recomp 41:00 NPP vs Deca | Are They Equal Mg for Mg? 44:20 Managing a Bulk & Adding an Oral Compound 47:35 Can Nandrolone Improve Mood? 48:45 Favorite Classic Cars & Modern Cars 54:00 Low Dose Deca with Low Dose Tren 56:10 Standard Contest Prep Steroid Cycles 57:30 Steroid Advice for "Average Gym Bros" vs Competitors 1:02:30 Dave the Fugitive Part 4 UK Blood Work Get your Labs done by Dave in the UK : https://evalbloodanalysis.com/home/ Support the Podcast Patreon — Help keep the show growing. Even $5/month makes a difference. https://www.patreon.com/thinkbigbodybuilding Sponsors TRUE NUTRITION — Custom supplements for serious lifters Use code THINK to save https://www.truenutrition.com/THINK STROM SPORTS — Performance supplements trusted by athletes UK: https://tinyurl.com/ydmbfa54 US: https://stromsportsus.com Supplement Source Canada — Top brand supplements with fast shipping http://www.supplementsource.ca Merch Official THINK BIG Merch — Train, represent, support the brand https://think-big.printify.me/products

Dr. Jason Tucciarone and Dr. Alan Schatzberg (Stanford University, Stanford, CA) join AJP Audio to discuss the use of low-dose buprenorphine as an adjunctive therapy to extend the anti-suicidal effects of ketamine treatment in patients with major depressive disorder and suicidal ideation.  AJP Editor-in-Chief Dr. Ned Kalin joins to discuss the rest of the June issue of the Journal, which takes a close look at issues surrounding suicide and severe depression. 01:20     Tucciarone and Schatzberg interview 03:36     Disparity between effects on suicidal ideation and antidepressant ratings 05:36     Ethics of placebo and ketamine in patients with suicidal ideation 08:28     Immediate clinical implications 11:40     Limitations 14:10     Further research 16:19     Kalin interview 16:24     Tucciarone et al. 20:39     Rovers et al. 24:30     Jelen et al. Transcript Board-certified psychiatrists, if you're seeking meaningful inpatient work with real clinical autonomy, consider becoming the Clinical Director for a 16-bed behavioral health hospital in Fergus Falls or Bemidji, Minnesota. You'll lead a supportive interdisciplinary team, enjoy predictable work-life balance, and have opportunities for teaching and mentorship without RVU pressure or third-party billing. Learn more on APA's Career Center, JobCentral, by searching Direct Care and Treatment – State of Minnesota. Direct Care and Treatment – State of Minnesota:  bit.ly/DCTClinicalDirector Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis." LINK TO FULL TRANSCRIPT  

Hugues de ThéCollège de FranceOncologie cellulaire et moléculaireAnnée 2025-2026Colloque - Oxidative Stress in Cancer-Therapy Response:From Oxidative Stress to Stem Cell Dysfunction: The Impact of Low-Dose Irradiation on Hematopoietic Stem CellsNathalie GaultCEA, Direction de la Recherche Fondamentale, Institut de Biologie François Jacob - Laboratoire d'Étude de la Niche, du Cancer et des Radiations dans l'Hématopoïèse, Fontenay aux Roses, France

Full article: Artificial Intelligence–Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial Pragmatic data obtained in clinical settings can add further insights into how AI shapes radiology practice. Hira Qureshi, MD, discusses the AJR article by Hwang et al. that reports a prospective randomized trial of the impact of AI for low-dose chest CT interpretation.

Show notes at pharmacyjoe.com/episode1129 In this episode, I’ll discuss the incidence of torsades from low-dose ondansetron in perioperative patients.

Watch Here : https://www.youtube.com/watch?v=F5G6lxmNrf0 Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

On this episode of The Vitamin Professor Podcast, Professor Gene Bruno talks to Suresh Lakshmikanthan, PhD, BPharm at Natural Remedies.Suresh Lakshmikanthan, PhD, BPharm, chief business officer at Natural Remedies, leads global business strategy and operations across the company's pharmaceutical and nutraceutical divisions. With more than two decades of international experience, he is focused on advancing innovation and sustainable practices in botanical product development and commercialization.Lakshmikanthan holds a PhD in international business and leadership and an MBA in international business from Walden University, Minneapolis, MN. He earned his Bachelor of Pharmacy from Dr. M.G.R. Medical University, India. He has authored multiple research papers on international business and leadership, and his work continues to shape the intersection of global business strategy and botanical scienceThis podcast is brought to you in partnership with VRM Media and Nutraland USA, Inc. For more information about our host and guest, please see the below information.naturalremedieshumanhealth.com/ashwa-30/⁠https://nutralandusa.com/⁠linkedin.com/in/gene-bruno-ms-mhs-rh-ahg-2ab0508/⁠https://www.vrmmedia.com⁠@hnvirtual, #hnvirtual, #naturalremedies, #genebruno, #thevitaminprofessor, #ashwa-30Find our podcast on your favorite platform:podcasts.apple.com/us/podcast/the-vitamin-professor-podcast/id1746137375youtube.com/channel/UCxeQ-IuqCRmq0YLc7jQNMKAmusic.amazon.com/podcasts/a8a96593-b93c-48cf-9fe9-2891c4035dad/the-vitamin-professor-podcastiheart.com/podcast/269-the-vitamin-professor-podc-175888136/

Best steroid cycles for average gym bros in 2026—what's changed with gear availability and smarter dosing strategies. Dave Crosland & Scott McNally break down TRT-based cycles, orals, estrogen control, and real-world Q&A. If you want practical bodybuilding advice without the BS, this is it. 0:00 Best Steroid Cycle Ratios: Masteron vs Primobolan with Testosterone 0:40 Sponsor Message – Support the Show 1:30 Best Steroid Cycles for Average Gym Bros (2026 Update) 6:15 Equipoise Cycles: Low Testosterone and Estrogen Control Explained 10:30 Oral Steroids in Cycles: When and How to Use Them 15:20 TRT + Anadrol vs Higher Testosterone: Which Works Better? 17:25 Quick Life Update: Dave's Car Problems 17:50 TRT Plus Cycle Ratios: How to Structure Low Dose Stacks 20:00 Sublingual Orals: Faster Absorption and Real Effects 28:00 Fat Loss Cycles: Compounds for an Aggressive 60 lb Cut 32:40 MK-677 Explained: Is It Worth Using? 35:30 Anastrozole Side Effects: What to Watch Out For 37:45 Testosterone Dosing for Amateur Bodybuilders 43:10 Listener Comment: Postal Carrier Question 44:30 Blood Donation on Steroids: Is It Safe or Ethical? 46:10 Cycle Critique: Testosterone, NPP, Trenbolone Stack 48:10 Deca vs NPP: Stacking Strategies Explained 50:20 HCG Use: When It Makes Sense + TRT Applications 54:00 Real Talk: De-escalating Confrontations as a Bigger Guy 59:15 Stories from Dave's Time as a Bouncer 1:16:15 Behind the Scenes: Podcast Banter & Wrap-Up UK Blood Work Get your Labs done by Dave in the UK : https://evalbloodanalysis.com/home/ Support the Podcast Patreon — Help keep the show growing. Even $5/month makes a difference. https://www.patreon.com/thinkbigbodybuilding Sponsors TRUE NUTRITION — Custom supplements for serious lifters Use code THINK to save https://www.truenutrition.com/THINK STROM SPORTS — Performance supplements trusted by athletes UK: https://tinyurl.com/ydmbfa54 US: https://stromsportsus.com Supplement Source Canada — Top brand supplements with fast shipping http://www.supplementsource.ca Merch Official THINK BIG Merch — Train, represent, support the brand https://think-big.printify.me/products Merch Official THINK BIG Merch — Train, represent, support the brand https://think-big.printify.me/products

Send us Fan MailDr. Parvesh Garg, neonatologist and researcher specializing in necrotizing enterocolitis (NEC) and acute kidney injury (AKI) in preterm infants, shares more than a decade of work on two of the most understudied organ systems in the NICU. He explains why surgical NEC is an independent risk factor for long-term neurodevelopmental impairment, how aggressively managing hypotension at the time of diagnosis may protect both the brain and the kidneys, and why the severity of NEC-associated AKI should be used as a prognostic tool in counseling families. He also presents early but fascinating laboratory findings suggesting that low-dose dexamethasone — unlike high doses — may help limit intestinal epithelial loss once NEC has set in, drawing a parallel to what therapeutic hypothermia does for HIE: the event has happened, but the inflammatory cascade may still be containable.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Watch Here : https://www.youtube.com/watch?v=YvyImqE9Ooo Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

LBCT: Effect Of Low-dose Dobutamine Infusion On N-terminal Pro B-type Natriuretic Peptide In Risk Patients With Acute Myocardial Infarction (DOBERMANN-D) - A Randomized Clinical Trial

In episode 532 I chat with Dr Sorcha O'Connor. Sorcha is a neuroscientist and PhD graduate from Imperial College London, where she led the PsilOCD study investigating low-dose psilocybin for OCD.  We discuss Sorcha's background that led her to this work, what is psilocybin, the background to the study, what the actual study looked like for participants, the outcomes of the study, what's happening in the brain during a dose of psilocybin, future studies, how psychedelics may improve learning, integration sessions with a therapist, what people with OCD can take from this study, limitations of the study, and much more. Hope it helps. Show notes: https://theocdstories.com/episode/sorcha-532 The podcast is made possible by NOCD. NOCD offers effective, convenient therapy available in the US and outside the US. To find out more about NOCD, their therapy plans and if they currently take your insurance head over to https://go.treatmyocd.com/theocdstories Join many other listeners getting our weekly emails. Never miss a podcast episode or update: https://theocdstories.com/newsletter 

In this episode, Michelle Weiner, DO, MPH returns to share her expertise on low-dose ketamine for chronic pain. Dr. Weiner is double board-certified in Interventional Pain Medicine, Physical Medicine, and Rehabilitation. She is founder of Neuropain Health delivering personalized integrative care treating the root cause of pain and suffering, both physical and emotional, using a multidisciplinary biopsychosocial approach with many years of clinical experience with ketamine-assisted therapy. In this conversation, Dr. Weiner reframes chronic pain as more than a symptom of tissue damage, describing it instead as a complex sensory and emotional experience shaped by the brain, nervous system, and a person's broader life context. She explains how chronic pain can become entrenched through maladaptive neural network patterns, fear, stress, and identity-level beliefs, and argues that effective treatment must move beyond symptom suppression toward a biopsychosocial model that addresses suffering, function, and quality of life. Drawing on her clinical work, Dr. Weiner discusses how low-dose ketamine, when paired with preparation, integration, pain reprocessing therapy, somatic work, and functional movement, may help create a window of neuroplasticity that allows patients to interrupt rigid pain patterns and reconnect with their own capacity for healing.   In this episode, you'll hear: How Dr. Weiner understands chronic pain The "triple network model" of neuropsychiatric conditions and how Dr. Weiner applies this to thinking about chronic pain Why imaging, injections, and medications often fall short once pain has become chronic and centrally mediated The gate control theory of pain and how this relates to possible mechanisms of ketamine treatments of pain How ketamine may support chronic pain treatment by creating a temporary window of neuroplasticity that can be used for deeper therapeutic change What pain reprocessing therapy is and why Dr. Weiner sees it as a first-line intervention for many chronic pain conditions Patient stories from Dr. Weiner's practice where belief change was a key component of healing pain   Quotes: "Over time, when [pain] becomes chronic, it's no longer trying to alter the physical body, it's actually trying to reprocess what's happening in the brain." [3:47] "Ketamine for me started to become more interesting because I realized that this wind-up phenomenon that is so responsible for a lot of people's chronic pain can actually start to be reversed when we start using medications [like ketamine] that can change the balance of glutamate and GABA [neurotransmitters]." [14:26] "So I just started to think, how can we use the lowest dose of ketamine to create neuroplasticity, guide them in a way that they're able to move and shift the story, and then that's how you can create long term change.  [18:51]  "The key is to understand that we are our own healers. If we're not involved in actively participating in our treatment, then we're relying on someone else outside of us and that's not really a long term plan." [29:20] "More with ketamine is definitely not better. When people feel so disconnected and so separate from themselves, they can experience more fear. And I think that's important to have that sweet spot where they're able to get that time out. They're not really feeling their pain, they're not in their ordinary mind and their conscious thoughts and they're able to have the brain connect in a different way and experience things differently, which then creates hope and allows them to really wake up and say, 'oh, there there are other options out here for me.'" [30:11]   Links: Dr. Weiner's recent article "Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: a case series" Dr. Weiner's website: Neuropain Health Dr. Weiner on Instagram Dr. Weiner on LinkedIn Previous episode: Ketamine-Assisted Psychotherapy for Chronic Pain with Michelle Weiner, DO, MPH Psychedelic Medicine Association Porangui

In this episode of the Full of Beans Podcast, I'm joined by Professor Hubertus Himmerich, Consultant Psychiatrist and Reader in Eating Disorders at King's College London, and the principal investigator of the EDEN study.The EDEN study is the first study of its kind exploring whether low-dose oral ketamine, compared with placebo, could support people living with both anorexia nervosa and major depressive disorder.Depression affects around 50% of people with anorexia, and when low mood, anxiety and hopelessness are present, it can make recovery feel incredibly difficult. Traditional antidepressants often don't work well for people with anorexia, which is why researchers are exploring new approaches.What We Cover in This EpisodeWhy is depression so common in anorexia nervosaWhy SSRIs often don't work well in this populationThe science behind ketamine and how it affects brain plasticityWhy the EDEN study focuses on improving mood rather than weightHow depression can reduce hope and motivation in recoveryThe difference between medical ketamine treatment and recreational ketamine useHow the study has been shaped by people with lived experienceWhy new treatment approaches needed in the eating disorder fieldIf you're interested in taking part in the EDEN study, the team are currently recruiting participants! Please email eden@kcl.ac.uk to find out more!Connect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTube⚠️ Content Note: This episode includes discussion of eating disorders, depression, ketamine use and mental health treatment.. Please take care when listening.If you enjoyed this episode, don't forget to subscribe, rate, and share to help us spread awareness.Sending positive beans your way, Han

Send a text

Continuing with her theme of nutrient profiles, on this episode Karolyn talks with mental health expert Peter Bongiorno, ND, about low-dose lithium. How much do you know about this unique, specialized nutrient? What is it used for and how safe is it? Tune in to find out more. In addition to his clinical practice, Dr. Bongiorno is the author of several best-selling books and he is on a mission to revolutionize psychiatric care in this country.Five To Thrive Live is broadcast live Tuesdays at 7PM ET and Music on W4CS Radio – The Cancer Support Network (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).Five To Thrive Live Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

Light smoking is not harmless.

Did you know optimized sleep can transform your days by: ✅ Processing emotions & repairing your body overnight ✅ Waking up energized & clear-headed (no grogginess) ✅ Reducing stress, anxiety & evening wine cravings ✅ Supporting mood, hormones & long-term vitality In this episode, I sit down with Joseph Sheehey, former NASA engineer & founder of Cured Nutrition, to unpack cannabinoids for better rest. We clarify CBD, CBN, microdose THC, full-spectrum hemp — and why quality + herbal synergy make all the difference. Key highlights: Why sleep is essential for emotional processing, recovery & vibrant energy. CBD for calm, CBN for deep "weighted blanket" relaxation, microdose THC for gentle relief without impairment. How Cured's adaptogen-blended gummies outperform typical dispensary options (no paranoia, restored mornings). Joe's journey from depression & near-suicide to building a natural healing brand. The 2025 hemp regulation changes & what they mean for wellness-focused products. Ready for deeper, more restorative sleep? Visit HayleyHobson.com/cured — use code HAYLEY for 15% off (details in show notes). Resources: Shop & discount: HayleyHobson.com/cured (code: HAYLEY) Advocacy info: NCRCA.us Full transcript: Hayley Hobson's Podcast Connect: Instagram • Facebook • TikTok — subscribe for weekly tools to a 10/10 life. Share this with anyone struggling with sleep — and leave a review to help more women find it!

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

What makes methylene blue so different from most nootropics is how little it takes to have an effect. In this clip, Mark Sloan explains why ultra-low doses of methylene blue can support mental clarity, calm energy, and mitochondrial performance without overstimulation. You'll hear why: Just a few milligrams can support steady, all-day focus Low doses reduce risk while increasing safety and accessibility Methylene blue supports mitochondrial energy production at the cellular level It plays a role in the NAD to NADH ratio, a key marker of metabolic health The brain benefits disproportionately due to high energy demand Tune in to Episode 68, where we go deeper into methylene blue, mitochondria, metabolic health, and why low-dose strategies often outperform aggressive protocols. Links Watch it on YouTube: https://youtu.be/q5PBJJAypDQ Full episode : https://outliyr.com/68 Connect with Nick on social media Instagram Twitter (X) YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick  

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Are allergies silently draining your energy, wearing down your immune system, and keeping you stuck in a cycle of chronic symptoms? Allergies aren't just seasonal annoyances, they are abnormal immune reactions to everyday substances like pollens, molds, dust mites, animal dander, and even foods. When your body misidentifies these normal particles as threats, it triggers inflammation, congestion, infections, fatigue, skin issues, and respiratory problems that can worsen over time. Many people turn to antihistamines, decongestants, or steroids, but these only mask symptoms rather than address the root cause. In this episode, Dr. Hotze breaks down how allergies develop, why they tend to run in families, and how repeated exposure can overwhelm your immune system and lead to the “cycle of illness.” He also explains why antibiotics often exacerbate the problem by disrupting gut flora and fueling yeast overgrowth, which further weakens immunity. Most importantly, Dr. Hotze shares a proven, practical solution called low-dose immunotherapy, a targeted approach that helps block allergic reactions at the source. This therapy can dramatically reduce symptoms, including asthma, sinus infections, eczema, and chronic drainage, by retraining the immune system instead of suppressing it. If allergies are affecting your daily life, your mood, your sleep, or your overall well-being, there is a natural and effective way to restore your health. Low-dose immunotherapy may be the long-term relief you've been searching for. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

The topic of low-dose atropine, not FDA-approved, has become one of the most important conversations in pediatric eye care this year, especially as clinicians turn to the STAR Study for clarity on atropine's role in modern myopia control. The STAR Study is the largest and most ethnically diverse atropine study to date, evaluating 0.01% and 0.03% atropine versus placebo in more than 800 children across three countries.

Watch Here : https://www.youtube.com/watch?v=yJaFlYKLDUs Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

Watch Here : https://www.youtube.com/watch?v=oaqSZlgDtlY Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

I'm reposting episodes that were taken down from Spotify. This is a repost of the 2023 conversation. Keith sits down with Itarya Rosenberg to discuss growing up in Bucks County, discovering the local scene, our early show-going experiences, navigating depression and institutions in his high school years and Itarya's early work in Legendary Divorce. We also discuss the formation of Low Dose, the band's history, the end of Low Dose and the beginning of Rid of Me, the band's history, their latest LP "Access to the Lonely", addiction, alcoholism, mental health and more.  Artist Spotlight: Keith speaks to Tristan D'Graves from Incendiary Device about their new self titled LP on Bridge Nine Records  Intro: 0:00 - 6:39 Rid of Me Interview: 6:40 - 1:00:37 Incendiary Device Interview: 1:00:50 - 1:24:11 Outro:  1:24:25 - 1:29:08

In this video, I share my personal experience with low-dose radiation therapy for osteoarthritis and inflammatory knee pain — a treatment with a long history in Europe that's now being re-examined in the U.S. as a safe, evidence-based option for chronic orthopedic pain. Low-dose radiation therapy (LDRT) involves the use of very small, precisely targeted doses of radiation — typically one-tenth or less of what's used in cancer treatment — to reduce inflammation and modulate immune response in joints, tendons, and soft tissues. Research has shown that these low doses can help relieve pain and improve mobility, often providing durable results without the side effects of steroids or long-term medications. I'm joined by Dr. Sanjay Mehta, Radiation Oncologist at St. Joseph Cancer Center in Houston, to discuss the science behind this therapy, its mechanisms of action, and the clinical outcomes we're seeing today for conditions such as: • Osteoarthritis • inflammatory knee pain • Plantar fasciitis • Tennis elbow • Shoulder and joint pain You'll also see a glimpse of my own treatment session, as we explore how this “old yet new” approach is helping patients regain comfort, function, and quality of life — without medications or surgery. Resources: Dr. Sanjay Mehta, Radiation Oncologist St. Joseph Cancer Center https://drsanjaymehta.com/

Today's episode is one I've really been looking forward to because we're diving into something that's transforming the way we think about mental health treatment: low-dose ketamine therapy. My guest, Dr. Sharon Niv, is the co-founder of Joyous, a public benefit company helping make this kind of care more accessible and affordable than ever before. Sharon brings a fascinating background in cognitive psychology, meditation, and technology, and she's helping bridge the gap between neuroscience and therapy in a way that's incredibly gentle, safe, and empowering for both clients and clinicians. We'll talk about what makes psycholytic, or low-dose, ketamine different from traditional psychedelic experiences, how it can enhance the therapeutic process, and how you, as a therapist, can get trained to integrate it into your own work. This is one of those conversations that opens your mind to what's possible in therapy, so let's jump in. Resources Mentioned In This Episode Use the promo code "GORDON" to get 2 months of Therapy Notes free Consulting with Gordon The PsychCraft Network Profit First for Therapists Workbook Meet Sharon Niv, Ph.D. Dr. Sharon Niv is a cognitive psychologist and co-founder of Joyous Team, a Public Benefit Corporation dedicated to making evidence-based mental health treatments accessible and affordable. Her work bridges the worlds of neuroscience, technology, and therapy with a focus on how scalable, data-driven approaches can enhance emotional well-being. Dr. Niv earned her Ph.D. in Brain and Cognitive Science from the University of Southern California, where she conducted research on EEG biomarkers, neurofeedback, and the neural underpinnings of mood and behavior. She also holds a B.A. in Molecular and Cellular Biology from UC Berkeley and an M.A. in Clinical and Cognitive Psychology from USC. Before founding Joyous, Sharon worked on developing virtual-reality interventions for chronic pain and neurofeedback programs designed to help people improve emotional regulation and resilience. A long-time meditation practitioner, she combines scientific rigor with a deep understanding of mindfulness and experiential learning. Through Joyous, Sharon and her team are pioneering low-dose (psycholytic) ketamine therapy, creating safer, more sustainable pathways for individuals and therapists to experience healing and insight. Her mission is to empower both clinicians and clients with practical tools that promote neuroplasticity, compassion, and mental clarity. The Power of Therapy + Joyous Joyous Substack LinkedIn

Broadcast from KSQD, Santa Cruz on 10-09-2025: Dr. Dawn opens by addressing an emailer's question about safety of low-dose lithium for dementia prevention. She reports finding a two-year double-blind placebo-controlled trial of 61 patients with mild cognitive impairment that showed no kidney damage from therapeutic lithium doses. While low-dose lithium at 2-3 milligrams daily appears safe compared to therapeutic doses of 50-100 milligrams, she notes its calming effects may improve cognition. >/li> She discusses over-the-counter hearing aids now available without prescription, ranging from $98 to $999, representing significant savings compared to prescription models costing four times as much. >/li> An emailer asks about long-term methotrexate use for psoriasis, reporting declining white blood cell counts and slower healing. Dr. Dawn reviews studies showing that in 13-year rheumatoid arthritis trials, severe side effects occurred in only 3% of patients. She recommends monthly blood monitoring including comprehensive metabolic panels to check liver and kidney function. As an alternative, she suggests apremilast, which showed excellent long-term safety in pooled data from half a million patient years with virtually no liver, kidney, or blood count problems. She also recommends trying phototherapy with tuned red light frequencies and topical treatments before considering drugs like etanercept that carry leukemia and lymphoma risks. >/li> Dr. Dawn expands on ultra-processed food dangers, explaining how mechanical processing of carbohydrates accelerates digestion and causes blood sugar spikes that lead to insulin resistance. Steel-cut oatmeal and wheat berries digest slowly and accelerate glucose at a low rate, while instant oatmeal and white bread hit like loud spikes. She emphasizes that processing primarily affects carbohydrates, not proteins or fats. Whole fruits are vastly superior to juices because juicing makes fruit sugars unnaturally available to metabolism. She also warns about hidden microplastics entering food through processing equipment, transport tanks, and packaging, with longer processing and travel distances increasing contamination. >/li> Dr.Dawn discusses the health dangers of sedentary behavior, noting that simply walking 20 minutes daily can lower blood pressure without requiring intense exertion. Dr. Dawn offers creative exercise solutions including bouncing on inflatable exercise balls during screen time, keeping weights in bathrooms for tooth-brushing workouts or in other frequently used spaces, doing resistance band exercises while waiting in cars, and practicing single-leg squats for balance. She describes the geriatric "get up and go" test where inability to stand, walk 10 feet, return, and sit within 10 seconds predicts five-year mortality. >/li> A caller discusses motivation challenges with his unused NordicTrack equipment. Dr. Dawn suggests making exercise rewarding by listening to engaging podcasts exclusively during workouts, creating positive associations that build sustainable habits. She explains that five minutes daily for six days weekly, maintained for a month, typically becomes permanent. The caller correctly notes that exercise increases mitochondrial production, and Dr. Dawn expands on this, explaining how oxygen debt triggers DNA signals to build new muscle fibers and mitochondria, raising metabolic rate, improving glucose metabolism, and increasing brain-derived neurotrophic factor that promotes new neural connections, making exercise crucial for preventing cognitive decline. >/li>

Thoracic radiologists Jeffrey Kanne, Miranda Siemienowicz and Jonathan Chung discuss the current global status of lung cancer screening, offering tips and tricks for reading these studies. Meanwhile, Andrew and Frank talk about everything BUT pulmonary nodules: another shameful journal travesty, TB sniffer rats and ketamine epiphanies.   Lung cancer screening article ► https://radiopaedia.org/articles/lung-cancer-screening Retraction Watch - Tin Man Syndrome ► https://retractionwatch.com/2025/08/15/tin-man-syndrome-case-plagiarized-from-hoax-sleuths-say/ Those TB detecting rats ► https://apopo.org/what-we-do/detecting-tuberculosis Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Radiopaedia Community chat ► http://radiopaedia.org/chat Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

Low Dose is a specially-curated segment that combines the most interesting RHJ stories into one, bite-sized episode. Bypass all the fluff and get straight to the information you need to know. This week, we highlight the scientifically-backed strategies for manifesting your dream life, how the fashion industry is poisoning you, and a very real future where parents can design their own perfect baby. You can find more information about our guests and where to find each full episode below: 00:00-03:55 - The science to manifesting your dream life (Manifestation: Dr. James R. Doty ⁠⁠https://radiohealthjournal.org/manifestation-the-scientific-path-to-creating-your-dream-life/) 04:00-07:00 - How your clothes are poisoning you (Toxic Fashion: Alden Wicker ⁠https://radiohealthjournal.org/mercury-hats-arsenic-dresses-and-poisoned-shoes-toxic-fashion/) 07:00-10:00 - The future of genetically-modified humans. (Gene Editing: Dr. Elizabeth McNally https://radiohealthjournal.org/genomics-pt-2-designer-babies-illegal-experiments-and-moral-issues/) Learn more about your ad choices. Visit megaphone.fm/adchoices

In this powerful episode of the TIck Boot Camp Podcast, Dr. Jaquel Patterson, nationally recognized naturopathic physician and medical director of Fairfield Family Health, joins Matt Sabatello to explore the many layers of Lyme disease recovery – from hidden mold exposure to hormone balance and mental health support. Mold & Lyme Disease – Why mold toxicity can block Lyme recovery and how Dr. Patterson stages treatment so patients don't get overwhelmed. Hormone Health – The vital role hormones play in energy, mood, joint health, and the ability to fight chronic infections. Mental Health & Lyme – How inflammation impacts the brain, leading to panic attacks, anxiety, depression, and brain fog — and how those symptoms can reverse with healing. Low Dose Immunotherapy (LDI) – What it is, how it retrains the immune system to stop overreacting, and why it's helping Lyme patients stabilize. Inflammation & Flares – Practical tools like turmeric, hydration, and electrolytes to calm Herxheimer reactions and ease painful flare days. Environmental Toxins – How pesticides, polluted air, and contaminated water add to the burden — and realistic steps to reduce exposure.

Show notes at pharmacyjoe.com/episode1026. In this episode, I’ll discuss hallucinations from low-dose ketamine use in the ICU. The post 1026: Is the Low-Dose Ketamine In the Room With Us Right Now? appeared first on Pharmacy Joe.

Our bodies are exposed to about 20,000 hits of radiation from cosmic rays every second. Is that good or bad?

DNS Podcast Dave Crosland & Scott McNally 0:00 teaser 0:30 Intro and advertisers 1:45 Lots of Yawns today 2:20 Will Tariffs Impact Gear? 7:20 what sources are saying 16:25 Varying opinions on Low Dose 19:00 Have cycle expectations changed? 23:20 Should we block DHT on cycle? 28:15 Synthoil Comment 29:45 How long on TRT between blasts 33:00 Tips to break a Plateau 42:50 No Changes in weight or strength on anadrol? 45:30 Do we count ester weight when designing a cycle 49:30 l-carnatine and improved sperm 53:45 High Estrogen and Acne 57:30 Uncle Dave's Wisdom 1:03:15 Uncle Dave's Wisdom Bonus 1:06:00 Dave's App (linked below)

In this solo episode, I'm breaking down one of the most talked-about tools in the health optimization world right now—peptides. From healing faster to building lean muscle, improving fat loss, enhancing sleep, and even slowing down the aging process… peptides are powerful. But they're also misunderstood, under-regulated, and often misused. So in this episode, I'm walking you through exactly what peptides are, how they work, the most popular ones in each category, and both the pros and cons of using them. This is a no-BS, educational breakdown of everything you need to know before exploring peptides as a tool for better health, performance, or aesthetics. I also cover some legal and sourcing realities—because here's the truth: most peptides aren't FDA-approved, and you'll only find them labeled for “research purposes only.” This isn't an endorsement. It's a breakdown to help you make smarter, more informed decisions.   What I Cover in This Episode: What peptides are and how they're different from hormones or steroids Legal disclaimers and how they're commonly sourced Growth hormone peptides: CJC-1295, Ipamorelin, MK-677 Fat loss peptides: AOD 9604 and Tesamorelin Healing peptides: BPC-157 and TB-500 Anti-aging + cognitive peptides: GHK-Cu (Copper peptide), Epitalon, Semax, Selank Mitochondrial optimizer: MOTS-c and why it's a game-changer for metabolic health How to stack peptides and what to avoid Side effects, risks, and what to consider before diving in   Links & References: Biological Activities and Safety of Citrus spp. Essential Oils - Click Here Essential role of TRPC6 channels in G2/M phase transition and development of human glioma - Click Here   Final Take: Peptides can be a powerful tool—but they're not a magic bullet. If you're training hard, eating right, sleeping well, and want to push to the next level, they might offer that extra edge. Just make sure you're doing it smart, and not chasing shortcuts.   Register For 30-Strong - Register Here   Join The Collective - Join Here   Interested in working with a coach? Get a free nutrition consultation - Schedule Here   Join Us On Patreon - Join Here   Submit your questions to be featured on our Q&A episodes.   Order from Cured Supplement Order from Legion Supplements and get 20% off your first order by using discount code: keynutrition   Connect with us on Instagram Host Brad Jensen – @thesoberbodybuilder Next Level Nutrition – @mynextlevelnutrition   Episode Timestamps 00:00 "Peptides: Unapproved but Legally Sold" 04:38 Compounding vs. Big Pharma Conflict 07:44 Benefits of Growth Hormone 13:31 MK677's Effects on Body Composition 16:51 Water Retention from Low Dose? 18:30 Health Supplement: Benefits and Considerations 23:35 "GLP1s and Peptide Therapy Debate" 27:03 GHK-CU: Skin and Anti-Aging Benefits 28:14 Copper Peptides for Hair and Healing 32:39 Growth Hormones and Water Retention 34:41 Success with BPC and TB500 40:13 GLP1s Fat Loss: Efficacy Concerns 42:03 "Peptides vs. Steroids: Health Debate" 45:11 "Join the Daily Wellness Movement"

Whats the lowest effective dose of tren? Well, We are going to find out lol. Plus my experinece loading carbs on GLP-1 meds like retatrutide or semaglutide. DADA = Massive Endurance PLUS your listner questions! ✅ Coach Scott McNally hangs with you guys and talks shop. Reach out for coaching or show sponorship at : mcnallydiets@gmail.com

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Sanjay Mehta is a radiation oncologist with over 25 years of experience, and is currently the president of Century Cancer Centers in Houston, Texas (drsanjaymehta.com). In this episode, Sanjay explores the rapidly evolving field of radiation oncology, addressing common misconceptions about radiation exposure. He delves into radiation's critical role in modern oncology, examining recent advancements that precisely target tumors while minimizing damage to surrounding healthy tissues and reducing side effects, with specific insights into breast, prostate, and brain cancers. Sanjay discusses fascinating international practices involving low-dose radiation therapy for inflammatory conditions such as arthritis, tendonitis, and sports injuries, highlighting its effectiveness and potential for wider adoption in the United States. Wrapping up on a lighter note, Peter and Sanjay discuss their mutual passion for cars and reveal how this shared interest first brought them together. We discuss: How radiation oncology became a distinct, rapidly evolving medical specialty [2:45]; Defining radiation, ionizing vs. non-ionizing, and common misconceptions about radiation exposure [5:30]; How radiation doses are measured, real-world examples of radiation exposure, and safety practices [9:00]; Radiation doses from common medical imaging tests, and why benefits of routine imaging outweigh risks [14:15]; Therapeutic radiation oncology: the evolution of breast cancer treatment toward less invasive surgery combined with targeted radiation [23:30]; Modern radiation oncology treatments for breast cancer—minimizing risks and maximizing patient comfort and outcomes [27:15]; How advances in radiation dosing, technology, and treatment precision have significantly reduced side effects [39:45]; How breast implants affect radiation treatment [44:45]; Radiation therapy for prostate cancer: advancements in precision, effectiveness, and patient selection criteria [48:00]; Radiation therapy options for inoperable prostate cancer or those seeking alternatives to surgery, and a remarkable patient case study [55:15]; How patients can effectively evaluate and select a high-quality radiation oncologist [1:05:45]; Radiation therapy for brain cancer: the shift toward precise, targeted techniques that minimize cognitive side effects, and remaining challenges [1:08:30]; The origins of radiophobia and how it influenced perceptions of radiation use in medicine [1:18:00]; Treating chronic inflammatory conditions such as tendinitis, arthritis, and more with very low-dose radiation [1:23:45]; Using low-dose radiation to treat spine injuries, scar tissue, fibrosis, keloids, and more [1:30:00]; The current barriers preventing widespread adoption of low-dose radiation therapy for inflammatory conditions [1:35:45]; The durability and versatility of low-dose radiation therapy in treating chronic inflammatory and arthritic conditions [1:40:45]; Sanjay's talent as a drummer [1:44:45]; Peter and Sanjay's shared passion for cars and racing [1:47:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

DNS Podcast 261 Dave Crosland & Scott McNally 00:00 Detroit Pro Recap and Competitor Insights 05:41 Exploring Low Dose Steroid Cycles 22:04 Listener Questions and Personal Experiences 27:20 The Evolution of Anabolic Steroids 31:12 Anadrol and Cutting Cycles 35:30 Navigating the End of the World: An Effort Stack 40:17 Sperm Quality and Testosterone Therapy 45:22 Aromatase Inhibitors: When to Stop? 50:04 Stress Management and Productivity ✅ Amino Asylum code THINK for 20% off research chems, peptides, l-carnitine and more https://aminoasylum.shop/ref/122/ ✅ Parabolic Peptides Code THINK for 10% off SLU, Research Chems, Peptides & more https://parabolicpeptides.com